Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells

Breast Cancer Research and Treatment

Volumn 59, Issue 3, 2000, Pages 231-244

  Chadderton, Antony ^a   Villeneuve, David J ^a   Gluck, Stefan ^a,b,c   Kirwan Rhude, Angie F ^a   Gannon, Brian R ^b   Blais, David E ^b   Parissenti, Amadeo M ^a,b  

^a Northeastern Ontario Regional Cancer Centre   (Canada)

^b LAURENTIAN UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Apoptosis; Breast cancer; P glycoprotein; Paclitaxel; Resistance; Reversal; Valspodar

Indexed keywords

CASPASE; CASPASE 2; CASPASE 8; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; FLUOROURACIL; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LIPOCORTIN 5; PACLITAXEL; PROPIDIUM IODIDE; PROTEIN KINASE C; PROTEIN P53; VALSPODAR;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; CELL STRAIN MCF 7; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CYCLOSPORINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; P-GLYCOPROTEINS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0034093609     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006344200094     Document Type: Article

References (53)

1. 1. Seidman AD, Reichman BS, Crown JPA, Curie V, Hakes T B, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Lepore J, Marks L, Fain K, Southrada M, Onetta N, Arbuck S, Norton I: Paclitaxel as second and subsequent therapy for breast cancer. J Clin Onc 13: 1152-1159, 1995
2. 2. Crown J: Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer. Eur J Cancer 33: S15-S19, 1997 (Suppl 7)
3. 3. Wiseman LR, Spencer CM: Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 12: 305-334, 1998
4. 4. Wani MC, Taylor HL, Wall ME, Coggan P, McPhail AT: Plant antitumor agents V1. The isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia. J Am Chem Soc 93: 2325-2327, 1971
5. 5. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979
6. 6. De Brabander M, Geuens G, Nuydens R, Willebrords R, De Mey J: Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 78: 5608-5612, 1981
7. 7. Jordan MA, Toso RJ, Thrower D, Wilson, L: Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993
8. 8. Bhalla K, Ibrado AM, Tourkina F, Tang C, Mahoney ME, Huang Y: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7: 563-688, 1993
9. 9. Allen RT, Hunter WJ III, Agrawal DK: Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Meth 37: 215-228, 1997
10. 10. Janicke RU, Sprengart ML, Wati MR, Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998
11. 11. Saunders DE, Lawrence WD, Christensen C, Wappler NL, Ruan H, Deppe G: Paclitaxel-induced apoptosis in MCF-7 breast cancer cells. Int J Cancer 70: 214-220, 1997
12. 12. Chen G, Teicher BA, Frei E III: Differential interactions of P-glycoprotein inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole C1941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells. Anticancer Res 16: 3499-3505, 1996
13. 13. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162, 1976
14. 14. Beck WT, Mueller TJ, Tanzer LR: Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39: 2070-2076, 1979
15. 15. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992
16. 16. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361, 1994
17. 17. Harris AL, Hochhauser D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31: 205-213, 1992
18. 18. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR, Hickson, ID: Relationship between tomoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 15: 6592-6595, 1991
19. 19. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G: The multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666-1674, 1992
20. 20. Friesen C, Fulda S, Debatin KM: Deficient activation of the CD9S (APO-1/Fas) system in drug-resistant cells. Leukemia 11: 1833-1841, 1997
21. 21. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP: Levels of multidrug resistance (MDRI) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398, 1998
22. 22. Ogretmen B, Safa AR: Expression of the mutated p53 tumor supressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 14: 499-506, 1997
23. 23. Cai Z, Stancou R, Korner M, Chouaib S: Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 68: 535-546, 1996
24. 24. Jachez B, Nordmann R, Loor F: Restoration of taxol sensitivity of multi-drug resistant cells by the cyclosporine SDZ-PSC833 and the cyclopeptolide SDZ280-446. J Natl Cancer Inst 85: 478-483, 1993
25. 25. Arichnal-Mattheis A, Rzepka RW, Watanabe T, Kokob N, Itoh Y, Combates NJ, Bair KW, Cohen, D: Analysis of the interactions of SDZ-PSC83 3 ([3′-keto-BmtI]-VaI2-Cyclosporine), a multidrug resistant modulator, with P-glycoprotein. Oncol Res 7: 603-610, 1995
26. 26. Wang Z, Tung PS, Moran, MF: Association of P120 ras gap with endocytic components and colocalization with epidermal growth factor (EGF) receptor in response to EGF stimulation. Cell Growth Differ 7: 123-133, 1996
27. 27. Hubbard AL, Wall AD, Ma M: Isolation of rat hepatocyte plasma membranes. I. Presence of the Three Major Domains. J Cell Biol 96: 217-229, 1983
28. 28. Keating A, Toor P: Human long term bone marrow culture. In: Poclard JM (ed) Methods in Molecular Biology. Wiley-Liss, New York, Vol 5, 1990, p 331
29. 29. Mercille S, Massie B: Induction of apoptosis in nutrient-deprived cultures of hybridoma and myeloma cells. Biotech Bioeng 44: 1140-1154, 1994
30. 30. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148: 2207-2216, 1992
31. 31. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84: 1415-1420
32. 32. Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH, Goldsmith ME: Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47: 5141-5148, 1987
33. 33. Cowan KH, Batist G. Tulpule A, Sinha BK, Myers CE: Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 83: 9328-9332, 1986
34. 34. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan, KH: Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986
35. 35. Doroshow JH: Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun 135: 330-335, 1986
36. 36. Davies R, Budworth J, Riley J, Snowden R, Gescher A, Gant TW: Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. Br J Cancer 73, 307-315, 1996
37. 37. Yamashima T, Ohnishi T, Nakajima Y, Terasaki T, Tanaka M, Yamashita J, Sasaki T, Tsuji A: Uptake of drugs and expression of P-glycoprotein in the rat 9L glioma. Exp Brain Res 95: 41-50, 1993
38. 38. Eischen CM, Kottke TJ, Martins LM, Basil GS, Tung JS, Eamshaw WC, Leibson PJ, Kaufmann SH: Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood 90: 935-943, 1997
39. 39. Woods CM, Zhui J, McQueney A, Bollag D, Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53 independent apoptotic pathway. Molec Med 95: 1076-1151, 1995
40. 40. Strobel T, Swanson L, Korsmeyer S, Cannistra SA: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 93: 14094-14099, 1996
41. 41. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R: Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 50: 1536-1540, 1996
42. 42. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M: p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57: 870-874, 1997
43. 43. Jones NA, Turner J, McIlwrath AJ, Brown R. Dive C: Cisplatin-and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 53: 819-826, 1998
44. 44. Zaffaroni N, Silvestrini R, Orlandi L, Bearzatto A, Gornati D, Villa R: Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br J Cancer 77: 1378-1385, 1998
45. 45. Bachman CA, Bills DA, Majumdar SK: Evidence of p53-induced apoptosis in cancer cells exposed to taxol. In Vitro Cell Dev Biol Anim 34: 434-435, 1998
46. 46. Torres K, Horwitz SB: Mechanisms of taxol-induced cell death are concentration dependent. Cancer Res 58: 3620-3626, 1998
47. 47. Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M: Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br J Cancer 77: 404-411, 1998
48. 48. Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T: p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci USA 94: 9679-9683, 1997
49. 49. Rodi DJ, Janes RW, Sangance HJ, Holton RA, Wallace BA, Makowski L: Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol 285: 197-203, 1999
50. 50. Thornberry NA, Lazebnik Y: Caspases: enemies within. Science 281: 1312-1316, 1998
51. 51. Fan W: Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57: 1215-1221, 1999
52. 52. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 18: 1308-1314, 1996
53. 53. Scudiero DA, Monks A, Sausville BA: Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst 90: 862, 1998